Metabolites derived from gut microbiota mitigate chemoresistance in pancreatic cancer

Area of Science:

• Oncology
• Microbiome research
• Metabolomics

Background:

• Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer mortality.
• The gut microbiota's role in cancer immunity and drug response is increasingly recognized.
• Understanding host-microbe interactions is crucial for novel cancer therapies.

Purpose of the Study:

• To investigate the association between gut microbiota composition and chemotherapy response in metastatic PDAC (mPDAC).
• To explore the role of microbial metabolites, specifically indole-3-acetic acid (3-IAA), in modulating chemotherapy sensitivity.
• To analyze the mechanisms by which 3-IAA influences tumor cell behavior and chemoresistance.

Main Methods:

• Systematic literature review of studies on microbiota, metabolites, and PDAC.
• Analysis of distinct gut microbiota profiles in chemotherapy-responsive versus non-responsive mPDAC patients.
• Investigation of the metabolic pathways involving tryptophan, 3-IAA, and its interaction with host factors like myeloperoxidase.

Main Results:

• Chemotherapy-responsive mPDAC patients exhibit elevated levels of the bacterial metabolite 3-IAA.
• 3-IAA promotes tumor cell death by increasing reactive oxygen species and inhibiting autophagy.
• Myeloperoxidase facilitates 3-IAA's cytotoxic effects on tumor cells.

Conclusions:

• The gut microbiota metabolite 3-IAA shows potential as a predictive biomarker for chemotherapy response in PDAC.
• Targeting microbial metabolites like 3-IAA could offer new strategies to overcome chemotherapy resistance.
• Further research into the gut-cancer axis may improve therapeutic outcomes for PDAC patients.